Skip to main content

Table 1 Clinical characteristics at diagnosis of primary BC in the 18 patients who subsequently became metastatic (Cases) and in the 18 matched non metastatic patients (Controls). The p-values for comparison were not reported for the matching factors

From: Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study

Patients characteristic

Cases

Controls

Overall

p

(n = 18)

(n = 18)

(n = 36)

n

(%)

n

(%)

n

(%)

T (primary)

1

9

(50.0)

9

(50.0)

18

(50.0)

 

2

8

(44.4)

8

(44.4)

16

(44.4)

 

3

1

(5.6)

1

(5.6)

2

(5.6)

 

N (positive lymph-nodes)

0

6

(33.3)

6

(33.3)

12

(33.3)

 

1

5

(27.8)

5

(27.8)

10

(27.8)

 

2

4

(22.2)

4

(22.2)

8

(22.2)

 

3

3

(16.7)

3

(16.7)

6

(16.7)

 

Stage at diagnosis

I

4

(22.2)

4

(22.2)

8

(22.2)

 

II

7

(38.9)

7

(38.9)

14

(38.9)

 

III

7

(38.9)

7

(38.9)

14

(38.9)

 

Luminal

A

12

(66.7)

12

(66.7)

24

(66.7)

 

B

6

(33.3)

6

(33.3)

12

(33.3)

 

Grading

      

0.5361

1

2

(11.1)

2

(11.1)

4

(11.1)

 

2

9

(50.0)

12

(66.7)

21

(58.3)

 

3

7

(38.9)

4

(22.2)

11

(30.6)

 

Adjuvant CT

      

0.4088

No

6

(33.3)

4

(22.2)

10

(27.8)

 

Antracycline

5

(27.8)

3

(16.7)

8

(22.2)

 

Antracycline + taxanes

7

(38.9)

11

(61.1)

18

(50.0)

 

Adjuvant HT

      

0.2146

No

1

(5.9)

0

(0)

1

(2.9)

 

Tamoxifen ± LHRH an

8

(47.1)

3

(16.7)

11

(31.4)

 

Letrozol

5

(29.4)

10

(55.5)

15

(42.9)

 

Anastrozol

3

(17.6)

4

(22.2)

7

(0.2)

 

Sequence of HT

0

(0)

1

(5.6)

1

(0.03)

 
 

mean

sd

mean

sd

mean

sd

 

Age (years)

64.5

16.7

64.3

14.1

64.4

11.7

0.9554

  1. CT chemotherapy, HT hormone-therapy, sd standard deviation